Unlearn Adds $12M for “Digital Twins” That Accelerate Clinical Trials

Speeding up and bringing down the cost of clinical trials would be a huge boon to pharma companies and patients alike.

San Francisco-based startup Unlearn.AI says it has developed proprietary technology that may help accomplish just that. On Monday the company announced it raised $12 million from investors who believe it stands out among the crowded field of tech outfits looking to tap into the huge amount of money spent conducting such studies.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.
Oops! Something went wrong while submitting the form.
Webinars

Applying Machine Learning to Increase Clinical Trial Efficiency: A Regulatory Journey

Press

Unlearn Closes $50 Million Series B Funding to Advance the Use of Its Machine Learning-Powered TwinRCTs™ in Clinical Trials

Press

Unlearn Signs Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany to Accelerate Immunology Trials using Twintelligent RCTs™

Collaborators will leverage AI-generated Digital Twins to enable smaller, more efficient pivotal clinical trials.
Led by Insight Partners, financing builds on the company’s momentum in working with leading biopharmaceutical companies to improve clinical trial efficiency.
Learn about the evolution of ideas that led to our TwinRCT™ solution for smaller, more efficient clinical trials and recent EMA draft qualification opinion.